Immunotherapy and cell therapy have revolutionized the field of cancer treatment by harnessing the power of the immune system to fight cancer cells. However, the development of effective immunotherapy drugs such as immune checkpoint inhibitors requires extensive preclinical testing to ensure safety and efficacy. Breakthroughs in the field are faced with several challenges including the generation of appropriate humanized mouse models for preclinical evaluation. Among others, genetically-engineered mouse models have emerged as valuable tools for improving cancer treatment outcomes.
Genetically Engineered Humanized Mouse Models: A Critical Tool for Studying Immunotherapy Drugs
July 13, 2023
- Controls in Flow Cytometry
- The Cost of Delay: Quantifying the Financial Impact of Inefficient Clinical Trial Start-Up
- TD2 Routine Analysis and More
- Specimen Stability Considerations During Flow Cytometry Assay Development, Optimization and Validation
- Fluorescent Cell Barcoding Using Flow Cytometry For High Throughput Testing
The Cost of Delay: Quantifying the Financial Impact of Inefficient Clinical Trial Start-Up
Clinical trial start-up delays are not just operational hurdles—they can result in significant financial losses. In oncology trials, where timelines ...
TD2 Routine Analysis and More
By Jennifer J. Stewart, PhD
Get Started
Contact Us Today!
If you’re looking for an expert team to guide your trial with efficiency in mind, we can help. As the creators of the Dynamic Trial, TD2 provides start-to-finish support with trial strategy, design and execution for faster go-to-market potential.